SG11202006945PA - Compounds for the treatment of kinase-dependent disorders - Google Patents
Compounds for the treatment of kinase-dependent disordersInfo
- Publication number
- SG11202006945PA SG11202006945PA SG11202006945PA SG11202006945PA SG11202006945PA SG 11202006945P A SG11202006945P A SG 11202006945PA SG 11202006945P A SG11202006945P A SG 11202006945PA SG 11202006945P A SG11202006945P A SG 11202006945PA SG 11202006945P A SG11202006945P A SG 11202006945PA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase
- compounds
- treatment
- dependent disorders
- disorders
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001419 dependent effect Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| US201862622629P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015289 WO2019148036A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006945PA true SG11202006945PA (en) | 2020-08-28 |
Family
ID=65409542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006945PA SG11202006945PA (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (es) |
| EP (1) | EP3743068A1 (es) |
| JP (2) | JP7307733B2 (es) |
| KR (1) | KR20200124678A (es) |
| CN (1) | CN112312909A (es) |
| AU (1) | AU2019212719A1 (es) |
| BR (1) | BR112020015199A2 (es) |
| CA (1) | CA3088127A1 (es) |
| CL (1) | CL2020001930A1 (es) |
| CO (1) | CO2020010467A2 (es) |
| CR (1) | CR20200355A (es) |
| IL (2) | IL302626A (es) |
| MA (1) | MA51672A (es) |
| MX (2) | MX2020007759A (es) |
| PE (1) | PE20210044A1 (es) |
| PH (1) | PH12020551059A1 (es) |
| SG (1) | SG11202006945PA (es) |
| WO (1) | WO2019148036A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7480048B2 (ja) | 2018-01-26 | 2024-05-09 | エグゼリクシス， インコーポレイテッド | キナーゼ依存的障害を処置するための化合物 |
| PE20210044A1 (es) * | 2018-01-26 | 2021-01-08 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| BR112020015201A2 (pt) * | 2018-01-26 | 2020-12-29 | Exelixis, Inc. | Compostos para tratamento contra distúrbios dependentes de quinase |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| CN115244041A (zh) * | 2020-03-10 | 2022-10-25 | 南京明德新药研发有限公司 | 乙烯基取代吡啶类化合物 |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DK0817775T3 (da) | 1995-03-30 | 2001-11-19 | Pfizer | Quinazolinderivater |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| CZ295468B6 (cs) | 1996-04-12 | 2005-08-17 | Warner-Lambert Company | Polycyklické sloučeniny |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| BRPI0412262A (pt) | 2003-07-23 | 2006-09-19 | X Ceptor Therapeutics Inc | derivados de azepina como agentes farmacêuticos |
| ES2466818T3 (es) * | 2003-09-26 | 2014-06-11 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| EP1871417B1 (en) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA2645137A1 (en) | 2006-03-07 | 2007-09-13 | James F. Blake | Heterobicyclic pyrazole compounds and methods of use |
| EP2532657B9 (en) * | 2008-10-14 | 2017-04-19 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| WO2011051276A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
| EP2493917B8 (en) | 2009-10-26 | 2020-03-04 | Externautics S.P.A. | Breast tumor markers and methods of use thereof |
| US10288617B2 (en) | 2009-10-26 | 2019-05-14 | Externautics Spa | Ovary tumor markers and methods of use thereof |
| US20120322075A1 (en) | 2009-10-26 | 2012-12-20 | Externautics S.P.A. | Lung Tumor Markers and Methods of Use Thereof |
| WO2011051271A2 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Prostate tumor markers and methods of use thereof |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| WO2012006960A1 (en) * | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| WO2014198919A2 (en) | 2013-06-14 | 2014-12-18 | Externautics S.P.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| US20150202291A1 (en) | 2013-11-05 | 2015-07-23 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| PT3134084T (pt) | 2014-04-25 | 2021-05-11 | Exelixis Inc | Método de tratamento de adenocarcinoma do pulmão |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN107235896B (zh) | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| CA3086522A1 (en) | 2017-12-20 | 2019-06-27 | Angex Pharmaceutical, Inc. | Carbamate and urea compounds as multikinase inhibitors |
| PE20210044A1 (es) * | 2018-01-26 | 2021-01-08 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
-
2019
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/en active Application Filing
- 2019-01-25 CN CN201980021547.0A patent/CN112312909A/zh active Pending
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
- 2019-01-25 IL IL302626A patent/IL302626A/en unknown
- 2019-01-25 KR KR1020207024577A patent/KR20200124678A/ko not_active Application Discontinuation
- 2019-01-25 AU AU2019212719A patent/AU2019212719A1/en active Pending
- 2019-01-25 CA CA3088127A patent/CA3088127A1/en active Pending
- 2019-01-25 BR BR112020015199-8A patent/BR112020015199A2/pt unknown
- 2019-01-25 EP EP19704968.7A patent/EP3743068A1/en active Pending
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
-
2020
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-13 IL IL276028A patent/IL276028A/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP2023082042A/ja active Pending
- 2023-06-13 US US18/334,113 patent/US20230374024A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200124678A (ko) | 2020-11-03 |
| IL302626A (en) | 2023-07-01 |
| BR112020015199A2 (pt) | 2021-05-04 |
| CO2020010467A2 (es) | 2020-10-30 |
| US20230374024A1 (en) | 2023-11-23 |
| CA3088127A1 (en) | 2019-08-01 |
| JP2021511359A (ja) | 2021-05-06 |
| US20210040099A1 (en) | 2021-02-11 |
| MX2022014351A (es) | 2022-12-13 |
| US11708367B2 (en) | 2023-07-25 |
| CL2020001930A1 (es) | 2020-12-11 |
| JP2023082042A (ja) | 2023-06-13 |
| WO2019148036A1 (en) | 2019-08-01 |
| IL276028A (en) | 2020-08-31 |
| PH12020551059A1 (en) | 2021-05-31 |
| CR20200355A (es) | 2021-02-22 |
| AU2019212719A1 (en) | 2020-08-20 |
| MX2020007759A (es) | 2020-09-24 |
| PE20210044A1 (es) | 2021-01-08 |
| MA51672A (fr) | 2020-12-02 |
| JP7307733B2 (ja) | 2023-07-12 |
| CN112312909A (zh) | 2021-02-02 |
| EP3743068A1 (en) | 2020-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276032A (en) | Compounds for the treatment of kinase-dependent disorders | |
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| IL271085A (en) | Bacteria to treat disorders | |
| IL276398A (en) | Combined treatment for mastocytosis | |
| IL276028A (en) | Compounds for the treatment of kinase-dependent disorders | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| HK1256721A1 (zh) | 用於治療眼部病症的化合物和組合物 | |
| IL276482A (en) | Compounds for pain management | |
| IL283948A (en) | Methods for treating depression | |
| IL290955A (en) | Compounds for the treatment of glycogen storage diseases | |
| SG11202100092QA (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS | |
| IL267818A (en) | Methods for treating neurological disorders | |
| ZA202002993B (en) | Compounds for the treatment of neuromuscular disorders | |
| IL281244A (en) | Therapeutic combination for the treatment of liver diseases | |
| EP3619204A4 (en) | COMPOUNDS FOR TREATING RESPIRATORY DISEASES | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| IL280243A (en) | Compounds similar to 17beta-heterocyclyl-digitalis for the treatment of heart failure | |
| PT3724173T (pt) | Compostos para o tratamento de distúrbios neuromusculares | |
| SG11202007642RA (en) | Treatment of disorders with tasimelteon | |
| GB201701928D0 (en) | Compounds for the treatment of hyperglycaemia | |
| AU2017901647A0 (en) | Compounds for the treatment of respiratory diseases | |
| AU2017901611A0 (en) | Compounds for the treatment of respiratory diseases | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes |